Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. 

Pharmaceutical

Paradigm Biopharma

Paradigm Biopharma's headquarters in Melbourne, Australia

Paul Rennie

Simon White

Donna Skerrett

John Gaffney

Amos Meltzer

Kevin Hollingsworth

The Leadership Team at Paradigm Biopharma drives the strategic direction of the company, overseeing key areas such as medical research, financial management, regulatory compliance, and scientific innovation. Composed of senior executives, including the Chief Medical Officer and Chief Financial Officer, the team collaborates to advance the repurposing of pentosan polysulphate sodium (PPS) and ensure its effective application in treating inflammation-related diseases. Their collective expertise shapes the company's vision and fosters partnerships to accelerate the development of transformative therapies.

Leadership Team

The Clinical Operations Team at Paradigm Biopharma is responsible for the strategic planning, implementation, and management of clinical trials focused on the repurposing of pentosan polysulphate sodium for inflammatory diseases. This team ensures the trials are conducted efficiently and in compliance with regulatory standards, overseeing patient recruitment, data collection, and collaboration with healthcare professionals to advance the development of innovative therapeutic solutions.

Clinical Operations Team

The Regulatory and Scientific Affairs Team at Paradigm Biopharma is responsible for ensuring compliance with regulatory requirements while guiding the scientific development of repurposed therapies. This team collaborates closely with research and development to translate scientific findings into actionable regulatory strategies, engages with regulatory bodies, and supports the business operations to facilitate successful clinical trials and product approvals aimed at treating inflammation-related diseases.

Regulatory and Scientific Affairs Team

The Finance and Investor Relations Team at Paradigm Biopharma is responsible for managing the company's financial strategies, reporting, and compliance, ensuring transparency with stakeholders and investors. They facilitate communication between the business and the investment community, providing insights into the company's financial performance and future prospects, while also overseeing corporate governance and regulatory obligations.

Paradigm Biopharma

Org chart

Board & advisors

Teams

Leadership Team

Clinical Operations Team

Regulatory and Scientific Affairs Team

Finance and Investor Relations Team

Offices

Similar companies